The go-to-partner for US and European biotech with innovative rare disease assets

Immedica’s business model is built on partnerships. It is and will remain one of the cornerstones and key driver for our continued commercial success and future growth.

Since 2018, Immedica has executed 15 successful deals including acquisition of assets, strategic licensing as well as distribution agreements. Immedica’s team has a long and proven track record of operating in mutually fruitful commercial partnerships, including US biotech as well as European companies, and our company possesses large experience from, and flexibility on, different alliance structures.

Full commitment and support

Under a partnership with Immedica, assets get full commitment and support. Our principal philosophy is that everything we do should add value for our customers and partners and most importantly the patients. 

A close collaboration, transparent communication and a problem-solving mentality are all key factors for a successful project. Our focus on partnering excellence is reflected in outstanding partner satisfaction, which is measured on a yearly basis.

People shaking hands

 

Bringing treatments to patients with an unmet medical need is in the very core of our business.

Our current partnerships are key, but we continuously scan the market for new investment opportunities. We have an ongoing dialogue with several companies that possess assets where we believe that we, in the Immedica region, can create value for all relevant stakeholders, starting with the patient. On an annual basis, Immedica conducts a large number of evaluations of new interesting business opportunities.

Bringing treatments to patients with an unmet medical need is in the very core of our business and to be able to deliver on this, partnerships are essential. That is why a significant part of our operations is dedicated to business development and evaluation of potential transactions.

Headquarter
Contact details
Local contacts
Contact details